E-viri
Recenzirano
Odprti dostop
-
Isshiki, Kyohei; Kamiya, Takahiro; Endo, Akifumi; Okamoto, Kentaro; Osumi, Tomoo; Kawai, Toshinao; Arai, Katsuhiro; Tomizawa, Daisuke; Ohtsuka, Kazuo; Nagahori, Masakazu; Imai, Kohsuke; Kato, Motohiro; Kanegane, Hirokazu
International journal of hematology, 04/2022, Letnik: 115, Številka: 4Journal Article
Vedolizumab, an immunosuppressive drug that acts locally on the gastrointestinal tract, is mainly used for the treatment of inflammatory bowel disease, and has been reported to be effective against gastrointestinal acute graft-versus-host disease (GI-aGVHD) in adults. However, there is insufficient evidence for pediatric GI-aGVHD. We used vedolizumab to treat three cases of GI-aGVHD in patients aged 1.5–4.4 years. It was significantly effective in two patients and did not cause serious side effects in any patient. Vedolizumab might be effective and safe for pediatric GI-aGVHD refractory to other treatments, but this must be confirmed in future studies.
